On May 1, 2024 Calidi Biotherapeutics Inc. (NYSE American: CLDI) ("Calidi"), a clinical-stage biotechnology company developing a new generation of targeted immunotherapies, reported the acceptance of three abstracts that will be presented in a poster session at the 2024 American Society of Clinical Oncology (ASCO) (Free ASCO Whitepaper) Annual Meeting, taking place from May 31-June 4, 2024, in Chicago, Illinois (Press release, Calidi Biotherapeutics, MAY 1, 2024, View Source [SID1234642543]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
The posters will include an update from a City of Hope-led Phase 1 study of Calidi’s CLD-101 program, focusing on the treatment of recurrent high-grade glioma, now advancing into its fourth cohort of participants. CLD-101 is a cutting-edge therapeutic candidate in Calidi’s NeuroNova program, comprising tumor-tropic neural stem cells (NSCs) that deliver an oncolytic adenovirus – CRAd-S-pk7 – selectively to tumor sites.
Calidi will also present preclinical data highlighting its RTNova delivery platform, a novel systemic enveloped oncolytic virotherapy program designed to target all tumor sites, and its CLD-201 program, which is expected to dose its first patient in a Phase 1 trial in the second half of 2024 subject to Calidi’s ability to raise additional capital.
Details on the posters and corresponding abstracts are shown below.
Poster Title: Phase 1 study of multiple intracerebral doses of a neural stem cell-based oncolytic virotherapy for treatment of recurrent high-grade gliomas
Abstract Number: TPS2102
Session Title: Central Nervous System Tumors
Session Date and Time: June 1, 2024, from 9:00 AM to 12:00 PM CDT
Poster Title: Transforming tumor immune microenvironments with a novel systemic enveloped oncolytic virotherapy targeting all tumor sites
Abstract Number: 2559
Session Title: Developmental Therapeutics – Immunotherapy
Session Date and Time: June 1, 2024, from 9:00 AM to 12:00 PM CDT
Poster Title: Non-clinical evidence supporting the upcoming CLD-201 clinical trial: Cell-based oncolytic virotherapy for multiple solid tumors
Abstract Number: 2553
Session Title: Developmental Therapeutics – Immunotherapy
Session Date and Time: June 1, 2024, from 9:00 AM to 12:00 PM CDT
Copies of the posters will be available on the Publications section of Calidi’s website following presentation at the meeting.